We are live on ! Find out more
LABP

Landos Biopharma, Inc. Common Stock
LABP

Delisted

LABP was delisted on the 23rd of May, 2024.

Back to rankings

Fund managers haven’t disclosed any holdings of LABP yet.

LABP Hedge Fund Activity: Q2 2024 in Review

0 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q2 2024, worth a combined $0 — down 100% from $34.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of LABP and 0 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Perceptive Advisors, exiting entirely with an estimated $31.9M sold.

  • 0 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q2 2024, down from 16 in Q1 2024.
  • Funds reported $0 of Landos Biopharma, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Landos Biopharma, Inc. Common Stock positions in Q2 2024 and 16 closed out, a net change of -16 holders.
  • The largest Landos Biopharma, Inc. Common Stock seller in Q2 2024 was Perceptive Advisors, an estimated $31.9M sold.

Based on aggregated 13F filings for Q2 2024.